Surmodics Expects FY24 Sales Of $117M-$121M, And $113M-$117M, Excluding SurVeil DCB License Fee Revenue, Compared To The Prior Guidance Of $116M-$121M, And $112M-$117M, Respectively, And The Consensus Of $119.26M
Portfolio Pulse from Benzinga Newsdesk
Surmodics has updated its FY24 sales expectations to $117M-$121M, including SurVeil DCB license fee revenue, and $113M-$117M excluding it. This is a slight adjustment from the prior guidance of $116M-$121M and $112M-$117M, respectively. The new forecast is closely aligned with the consensus estimate of $119.26M.
February 01, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Surmodics adjusted its FY24 sales forecast, showing a slight improvement over previous guidance. The update is in line with consensus estimates.
The adjustment in Surmodics' FY24 sales forecast, especially the slight increase in the expected range, could be viewed positively by investors as it indicates a potential for growth and stability in the company's operations. The alignment with consensus estimates also adds a layer of validation to the company's projections, potentially increasing investor confidence in the accuracy of these forecasts.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90